Alnylam Pharmaceuticals, Inc. (LON:0HD2)
Market Cap | 39.76B |
Revenue (ttm) | 1.80B |
Net Income (ttm) | -232.90M |
Shares Out | n/a |
EPS (ttm) | -1.80 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 123 |
Average Volume | 120 |
Open | 383.95 |
Previous Close | 392.07 |
Day's Range | 380.00 - 398.92 |
52-Week Range | 209.75 - 401.66 |
Beta | n/a |
RSI | 82.46 |
Earnings Date | Aug 7, 2025 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]
Financial Performance
In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.
Financial numbers in USD Financial StatementsNews
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) continue to outperform market expectations. Amid a backdrop of growin...

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ALNY continue to outperform market expectations. Amid a backdrop of growing demand fo...
Alnylam: Amvuttra Is Just Getting Started
Alnylam Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation
Alnylam jumps on full year revenue guidance raise

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J...
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 15 years by 10.3% on an annualized basis producing an average annual return of 22.67%. Currently, Alnylam Pharmaceutic...

Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end...

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
Alnylam Pharmaceuticals (NASDAQ: ALNY) is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure. ...

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.

Alnylam Pharmaceuticals Names Garg R&D Chief
Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed E...

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted...

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case
The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court’s finding of noninfringement in favor of Moderna, Inc. (NASDAQ: MRNA) in its ongoing patent battle with...

Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field
Vutrisiran, recently FDA-approved for ATTR-CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S...

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 20 years by 12.14% on an annualized basis producing an average annual return of 20.3%. Currently, Alnylam Pharmaceutic...

Alnylam Issues 2024 Corporate Responsibility Report
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Gui...
Alnylam posts new Phase 3 data for heart disease therapy Amvuttra

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...